

Supplemental Table 1 Involved extranodal organs

Involved organs	n	%
Bone marrow	22	19.6
Lung	5	4.5
Liver	2	1.8

Supplemental Table 2 Complications

Complication	n	%
Coronary heart disease	2	1.8
Diabetes	9	8.0
Hypertension	18	16.1
Autoimmune disease	1	0.9
Chronic renal failure	1	0.9
HBV infection	13	11.6

Supplemental Table 3 Comparison of baseline clinical characteristics according to the AMR, AMC, and ALC cutoff values

Characteristics	LMR \leq 3.6 n=51	LMR $>$ 3.6 n=61	<i>P</i>	AMC \leq 0.6*10 ⁹ /L n=99	AMC $>$ 0.6*10 ⁹ /L n=13	<i>P</i>	ALC \leq 0.6*10 ⁹ /L N=15	ALC $>$ 0.6*10 ⁹ /L n=97	<i>P</i>
FLIPI			0.349			0.036			0.211
0-1	9 (11.5)	16 (13.5)		24 (22.1)	1 (2.9)		1 (3.4)	24 (21.6)	
2	16 (17)	21 (20)		35 (32.7)	2 (4.3)		6 (5)	31 (32)	
3-5	26 (22.5)	23 (26.5)		39 (43.3)	10 (5.7)		8 (6.6)	41 (42.4)	
FLIPI2			0.627			0.336			0.236
0-1	13 (11.8)	17 (18.2)		28 (27.6)	2 (2.4)		1 (1.8)	29 (28.2)	
2	5 (5.1)	8 (7.9)		11 (12)	2 (1)		2 (0.8)	11 (12.2)	
3-5	2 (3.1)	6 (4.9)		8 (7.4)	0 (0.6)		0 (0.5)	8 (7.5)	
Grade			0.373			0.284			0.947
1-2	27 (29.1)	37 (34.9)		58 (55.8)	6 (8.2)		7 (7.6)	57 (56.4)	
3	19 (16.9)	18 (20.1)		30 (32.2)	7 (4.8)		5 (4.4)	32 (32.6)	
Ki67%			0.529			0.253			0.253
\leq 50	32(33.3)	43 (41.7)		68 (65.9)	7 (9.1)		7 (9.1)	68 (65.9)	
$>$ 50	12(10.7)	12 (13.3)		19 (21.1)	5 (2.9)		5 (2.9)	19 (21.1)	
Rituximab treatment			1.000			0.699			0.017
Absence	9 (9.1)	11 (10.9)		17 (17.7)	3 (2.3)		6 (2.7)	14 (17.3)	
Presence	42 (41.9)	50 (50.1)		82 (81.3)	10 (10.7)		9 (12.3)	83 (79.7)	
Therapeutic effect			0.068			0.676			0.857
CR	29 (25.0)	9 (13.0)		50 (49.4)	25 (25.6)		6 (5.3)	2 (2.7)	
nCR	27 (31.0)	20 (16.0)		6 (6.6)	4 (3.4)		50 (50.7)	27 (26.3)	
Extranodal involvement			0.221			0.940			0.720
Absence	35 (31.9)	35 (38.1)		62 (61.9)	8 (8.1)		10 (9.4)	60 (60.6)	
Presence	16 (19.1)	26 (22.9)		37 (37.1)	5 (4.9)		5 (5.6)	37 (36.4)	
Complication			0.873			0.910			0.627
Absence	35 (34.6)	41 (41.4)		67 (67.2)	9 (8.8)		11 (10.2)	65 (65.8)	
Presence	16 (16.4)	20 (19.6)		32 (31.8)	4 (4.2)		4 (4.8)	32 (31.2)	

Supplemental Table 4 Comparison of OS according to cutoff values for baseline LMR, AMC, and ALC

OS	LMR \leq 3.6 n=44	LMR>3.6 n=54	AMC \leq 0.6*10 ⁹ /L n=91	AMC>0.6*10 ⁹ /L n=10	ALC \leq 0.6*10 ⁹ /L N=13	ALC>0.6*10 ⁹ /L n=88
1 year, %	0.933	1.000	0.978	0.900	0.923	0.977
3 years, %	0.800	0.946	0.901	0.700	0.692	0.909
5 years, %	0.800	0.946	0.901	0.700	0.692	0.909
7 years, %	0.747	0.946	0.877	0.700	0.593	0.909
10 years, %	0.597	0.883	0.839	0.000	0.593	0.759
Mean OS, m	98.2	135.7	129.4	83.4	96.3	128.1
95% CI, m	84.4-112.0	125.5-145.9	120.0-138.8	51.2-115.7	65.8-126.9	117.1-139.1
P value	0.014		0.012		0.023	

Supplemental Table 5 Clinical characteristics according to POD24 status

	POD24	No POD24	P
Patient number	27	77	
High-risk FLIPI	17 (63.0%)	27 (35.1%)	0.013
High-risk FLIPI2	5 (18.5%)	3 (3.9%)	0.003

High-risk FLIPI refers to FLIPI score ≥ 3 ; high-risk FLIPI2 refers to FLIPI2 ≥ 3 .